Topics
ArticleSmall tags, big advances: studying endogenous proteins in their native context
By combining CRISPR knock-in with small peptide tags, researchers can study proteins in their native cellular context, generating more predictive data for translational drug discovery.
ArticleCerebral organoids reveal how Ebola virus persists in neural tissue
How does Ebola virus survive long after recovery? A new study using human cerebral organoids explores viral persistence in neural tissue and the growing role of organoid models in drug discovery research.
NewsEuropean initiative aims to bring molecular dynamics into mainstream drug discovery
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
ReportContext is everything: how spatial biology is changing our understanding of disease
Researchers can now analyse individual cells in extraordinary detail, yet understanding disease often requires more than studying cells in isolation. This report explores how spatial biology is revealing aspects of disease biology that cannot be captured through individual cells alone, and what that could mean for biomarker discovery, immunotherapy and drug development.
WebinarWhat it takes to automate high-content imaging at scale
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
WebinarThe truth about AI in drug discovery: what the experts really think
AI is transforming drug discovery - but beyond the hype, what’s actually delivering results? In this expert-led webinar, industry leaders explore where AI is accelerating target identification, molecule design and hit discovery, while also confronting the real-world challenges of data quality, validation and adoption. Discover what’s working today, what still ...
WebinarCan One Peptide Change Pain Research? Meet the Tool Transforming Drug Discovery
Discover how a new peptide tool, WRPRFa, is helping researchers better understand pain pathways and accelerate the search for next-generation analgesics.
WebinarOvercoming Affinity and Expression Bottlenecks in TCR Discovery
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
- Article
Cerebral organoids reveal how Ebola virus persists in neural tissue
How does Ebola virus survive long after recovery? A new study using human cerebral organoids explores viral persistence in neural tissue and the growing role of organoid models in drug discovery research.
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a potential new approach for treating cardiovascular disease.
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
- Article
Small tags, big advances: studying endogenous proteins in their native context
By combining CRISPR knock-in with small peptide tags, researchers can study proteins in their native cellular context, generating more predictive data for translational drug discovery.
- News
European initiative aims to bring molecular dynamics into mainstream drug discovery
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
- Report
Context is everything: how spatial biology is changing our understanding of disease
Researchers can now analyse individual cells in extraordinary detail, yet understanding disease often requires more than studying cells in isolation. This report explores how spatial biology is revealing aspects of disease biology that cannot be captured through individual cells alone, and what that could mean for biomarker discovery, immunotherapy and drug development.
ArticleFlow-based human tumour models reveal immune responses missed by static culture
Static cultures may not tell the whole story when it comes to immunotherapy performance. Results from the Mera™ flow-based human tissue model show stronger T-cell activity and cytokine responses under physiological flow, highlighting the role of dynamic immune–tumour interactions in preclinical testing.
- Article
Small tags, big advances: studying endogenous proteins in their native context
By combining CRISPR knock-in with small peptide tags, researchers can study proteins in their native cellular context, generating more predictive data for translational drug discovery.
- Article
Cerebral organoids reveal how Ebola virus persists in neural tissue
How does Ebola virus survive long after recovery? A new study using human cerebral organoids explores viral persistence in neural tissue and the growing role of organoid models in drug discovery research.
- News
European initiative aims to bring molecular dynamics into mainstream drug discovery
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
- Report
Context is everything: how spatial biology is changing our understanding of disease
Researchers can now analyse individual cells in extraordinary detail, yet understanding disease often requires more than studying cells in isolation. This report explores how spatial biology is revealing aspects of disease biology that cannot be captured through individual cells alone, and what that could mean for biomarker discovery, immunotherapy and drug development.
- Article
Small tags, big advances: studying endogenous proteins in their native context
By combining CRISPR knock-in with small peptide tags, researchers can study proteins in their native cellular context, generating more predictive data for translational drug discovery.
- News
European initiative aims to bring molecular dynamics into mainstream drug discovery
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
- Report
Context is everything: how spatial biology is changing our understanding of disease
Researchers can now analyse individual cells in extraordinary detail, yet understanding disease often requires more than studying cells in isolation. This report explores how spatial biology is revealing aspects of disease biology that cannot be captured through individual cells alone, and what that could mean for biomarker discovery, immunotherapy and drug development.
- Article
Flow-based human tumour models reveal immune responses missed by static culture
Static cultures may not tell the whole story when it comes to immunotherapy performance. Results from the Mera™ flow-based human tissue model show stronger T-cell activity and cytokine responses under physiological flow, highlighting the role of dynamic immune–tumour interactions in preclinical testing.
- News
European initiative aims to bring molecular dynamics into mainstream drug discovery
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
ReportAI in Drug Discovery: Progress, Limits and What Comes Next
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
ArticleWhy targeted therapies are exposing the limits of animal models – and what comes next
Traditional preclinical models are struggling to keep pace with a new generation of targeted therapies. As regulators embrace new approach methodologies (NAMs), vascularised tissue platforms are offering a more human-relevant approach to predicting drug efficacy and safety.
ArticleWomen in STEM: resilience and leadership in rare disease research
Rare neurological diseases remain one of the most challenging areas in drug discovery, with many patients still lacking treatment options. Dr Nitza Thomasson discusses returning to Servier to lead its rare neurology therapeutic area and explains why resilience, curiosity and persistence are essential for those looking to build a meaningful career in STEM.